Horizon Therapeutics plc and MIT Solve announce the launch of the third annual Horizon Prize

Horizon Therapeutics plc and MIT Solve announce the launch of the third annual Horizon Prize

Riyadh – Horizon Therapeutics plc (Nasdaq: HZNP) today announced the launch of the third annual global innovation challenge, The Horizon Prize, powered by MIT Solve.

Each year, the Horizon Prize poses a challenge question, asking entrepreneurs and innovators worldwide to think creatively to solve a relevant issue in the rare disease community. One winner will be awarded a total of $150,000 in funding.

An estimated 85% of biomedical research funding is wasted because of inefficiencies, highlighting an opportunity to decrease waste and redundancies while increasing the impact of investments in research and development.1 This year’s question, “How can we decrease the environmental impact of the rare disease health care space and alleviate burdens for rare disease families?” seeks to find a wide variety of technology-based solutions that can address areas including, but not limited to:

- Improving the rare disease patient diagnostic journey (reducing time, cost, etc.)

- Enhancing efficiencies in clinical trials and research

- Reducing single-use products and unnecessary plastics and medical/hazardous waste throughout research and manufacturing

- Creating or promoting alternative packaging that may be reusable, recyclable or biodegradable without compromising sterility or safety

- Optimizing the transportation of supplies and treatments by addressing shipping inefficiencies, cold storage and last-mile delivery

Learn more and submit